This HTML5 document contains 57 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n7http://linked.opendata.cz/resource/drugbank/drug/DB08804/identifier/kegg-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n14http://linked.opendata.cz/resource/mesh/concept/
n17http://linked.opendata.cz/resource/drugbank/dosage/
n4http://linked.opendata.cz/resource/drugbank/drug/DB08804/identifier/kegg-drug/
n9http://linked.opendata.cz/resource/drugbank/drug/DB08804/identifier/drugbank/
n23http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n8http://linked.opendata.cz/resource/drugbank/drug/DB08804/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/resource/drugbank/medicinal-product/
n13http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n16http://www.drugs.com/cdi/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/resource/drugbank/drug/DB08804/identifier/wikipedia/
n21http://linked.opendata.cz/resource/drugbank/drug/DB08804/identifier/pharmgkb/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08804
rdf:type
n5:Drug
n5:description
C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of estradiol to resemble testosterone but less one carbon at the 19 position. It is a schedule III drug in the U.S.
n5:dosage
n17:271B559C-363D-11E5-9242-09173F13E4C5
n5:group
approved illicit
n5:indication
For the treatment of refractory deficient red cell production anemias, breast carcinoma, hereditary angioedema, antithrombin III deficiency, fibrinogen excess, growth failure and Turner's syndrome. It is also indicated in the prophylaxis of hereditary angioedema.
owl:sameAs
n20:DB08804 n23:DB08804
dcterms:title
Nandrolone decanoate
adms:identifier
n4:D00955 n7:C08154 n8:9296 n9:DB08804 n18:Nandrolone_decanoate n21:PA165958423
n5:mechanismOfAction
Nandrolone is an androgen receptor agonist. The drug bound to the receptor complexes which allows it to enter the nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects.
n5:synonym
Nandrolone 17β-decanoate Deca-durabolin 19-nortestosterone decanoate
n10:hasAHFSCode
n11:68-08-00
n5:proteinBinding
58%
n13:hasConcept
n14:M0044317
foaf:page
n16:nandrolone.html
n5:IUPAC-Name
n6:271B55A1-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B55A7-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B55A6-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B55A3-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B55A4-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B55A5-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B55B7-363D-11E5-9242-09173F13E4C5 n6:271B559F-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B55B9-363D-11E5-9242-09173F13E4C5 n6:271B559D-363D-11E5-9242-09173F13E4C5 n6:271B55A0-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B559E-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n6:271B55AD-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B55AE-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B55A8-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B55A9-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B55AB-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B55AA-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B55AC-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
360-70-3
n5:category
n5:containedIn
n12:271B559A-363D-11E5-9242-09173F13E4C5 n12:271B559B-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B55B3-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B55B5-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B55B6-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B55B8-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B55B2-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B55B1-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B55B4-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B55A2-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B55AF-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B55B0-363D-11E5-9242-09173F13E4C5